BoneResearch Phase

Osteogenic Growth Peptide (OGP)

Subcutaneous injection

Overview

Osteogenic Growth Peptide is a naturally occurring 14-amino acid peptide identified in serum that promotes osteoblast proliferation and differentiation. The peptide activates the MAP kinase signaling pathway and stimulates collagen synthesis in bone-forming cells.

Mechanism of Action

OGP also demonstrates hematopoietic activity, influencing stem cell differentiation in the bone marrow microenvironment. Synthetic analogs have been developed to enhance stability and receptor affinity for potential therapeutic applications in osteoporosis and fracture healing..

Research Summary & Key Findings

Preclinical studies in ovariectomized rats and other animal models have demonstrated increased bone formation, trabecular connectivity, and bone strength following OGP administration. In vitro experiments confirm dose-dependent stimulation of osteoblast proliferation and alkaline phosphatase activity. No clinical trials in humans have been published, and the peptide remains in preclinical development with ongoing research into optimized delivery systems and dosing regimens.

Clinical Status

Research Phase

Osteogenic Growth Peptide (OGP) is in the research phase with limited clinical data in humans. Current evidence is primarily derived from preclinical (animal or in vitro) studies.

Administration Routes

Subcutaneous injection

Related Peptides in Bone

Find a Provider

Find a verified provider who offers Osteogenic Growth Peptide (OGP) therapy in your area.

Browse Provider Map

Find a Pharmacy

Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply Osteogenic Growth Peptide (OGP).

Pharmacy Directory

Join the Association

Access exclusive peptide protocols, provider resources, and community support.

List Your Practice

Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol.